37793-53-6Relevant articles and documents
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope
Yamaguchi, Aiko,Anami, Yasuaki,Ha, Summer Y.Y.,Roeder, Travis J.,Xiong, Wei,Lee, Jangsoon,Ueno, Naoto T.,Zhang, Ningyan,An, Zhiqiang,Tsuchikama, Kyoji
, (2021)
Antibody-drug conjugates (ADCs) hold great therapeutic promise for cancer indications; however, treating tumors with intratumor heterogeneity remains challenging. We hypothesized that ADCs that can simultaneously target two different cancer antigens could
Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance
Dai, Yuxuan,Cai, Xingguang,Bi, Xinzhou,Liu, Chunxia,Yue, Na,Zhu, Ying,Zhou, Jiaqi,Fu, Mian,Huang, Wenlong,Qian, Hai
, p. 104 - 115 (2019)
The drug resistance and the poor water solubility are major limitations of paclitaxel (PTX) of based chemotherapy. To conquer the two problems, targeting folate (FA) receptor PTX-lytic peptides conjugates were synthesized and evaluated. Compared with PTX, FA-P3-PTX and FA-P7-PTX displayed significantly enhanced cell toxicity in many cancer cells, particularly drug resistant cancer cells MCF-7/PTX. FA-P7-PTX possessed stronger effect on cell toxicity (IC50 = 2.92 ± 0.2 μM), membrane disrupting activity and pro-apoptosis in MCF-7/PTX cells than FA-P3-PTX. Further investigation displayed that the anti-cancer mechanisms of FA-P3-PTX and FA-P7-PTX might be a mitochondrial impairment and caspase-3-dependent apoptotic cell death. Furthermore, the in vivo antitumor efficacy study confirmed that FA-P7-PTX performed more stronger potency in inhibition of tumors growth than PTX. The study demonstrated that conjugate FA-P7-PTX with superior properties for antineoplastic activity, which makes it a promising potential candidate for drug-resistant cancer therapy.
USES OF ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES
-
Paragraph 00347; 00348, (2021/09/03)
Described herein are anti-CD3 antibody folate bioconjugates and uses thereof in the treatment of diseases, conditions, and cancers.
ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES
-
Paragraph 00338-00340, (2020/03/23)
Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.